JP Morgan Chase
RIGL icon

JP Morgan Chase’s Rigel Pharmaceuticals RIGL Stock Holding History

JP Morgan Chase’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-6,750
Closed -$173K – 5970
2019
Q1 		$173K Sell
6,750
-3,250
-33% -$74.3K ﹤0.01% 4685
2018
Q4 		$230K Hold
10,000
– – ﹤0.01% 4527
2018
Q3 		$321K Buy
+10,000
New +$300K ﹤0.01% 4497

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's RIGL Position: Q2 2026 in Review

JP Morgan Chase increased its Rigel Pharmaceuticals (RIGL) stake by 1.4% in Q2 2026, buying an estimated $18.2K and bringing the position to 41,675 shares worth $1.63M. The position accounts for ﹤0.01% of the portfolio, ranked #4343.

JP Morgan Chase first reported a position in RIGL in Q2 2013 and has held it in 44 quarters since. The position peaked at $7.94M in Q3 2016. 156 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • JP Morgan Chase held 41,675 shares of Rigel Pharmaceuticals worth $1.63M as of Q2 2026.
  • JP Morgan Chase bought 591 Rigel Pharmaceuticals shares in Q2 2026, an estimated $18.2K.
  • Rigel Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #4343 holding.
  • JP Morgan Chase first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • JP Morgan Chase's Rigel Pharmaceuticals position peaked at $7.94M in Q3 2016.
  • 156 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.